Alvespimycin
Alvespimycin has been studied in 7 papers since 2017: none in people yet, 5 in animals, 1 in cells, 1 review. The research so far is in animals and cells. The newest paper, Dec 4, 2024: “Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells”.
See all 7 papers on alvespimycin
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country; 7 trials, none about aging, 6 with no results posted.
None of its findings points the other way.
- 1 lab in 1 country
- 7 trials, none about aging, 6 with no results posted
- Funders: Diabetes Australia and 2 more
- Animals5
- Cells1
What did mouse lifespan tests of alvespimycin find?
NIA ITPThe NIA Interventions Testing Program ran 1 arm in 2015; the change in median lifespan ran from −4% to +9%.
What did studies of alvespimycin find?
2Studies of alvespimycin measured 2 outcomes: tubulointerstitial fibrosis and cellular senescence.
Tubulointerstitial fibrosis
downin mice1
1 study
Tubulointerstitial fibrosis
downin mice1
Alvespimycin decreases tubulointerstitial fibrosis in diabetic mice following acute kidney injury.
“Treatment with alvespimycin alone reduced kidney senescence and levels of Col1a1, Acta2, Tgfb1, and Cd68”
Animalsin diabetic mice following acute kidney injurykidney
Clinical science (London, England : 1979)
Cellular senescence
downin mice1
1 study
Cellular senescence
downin mice1
Alvespimycin decreases cellular senescence in diabetic mice following acute kidney injury.
“Treatment with alvespimycin alone reduced kidney senescence and levels of Col1a1, Acta2, Tgfb1, and Cd68”
Animalsin diabetic mice following acute kidney injurykidney
Clinical science (London, England : 1979)
Has alvespimycin been tested in people?
0 of 7 about aging7 trials are registered, but no study of it in people has been published yet.
In trials
Phase 2Terminated3 trials
Phase 1Completed2 trials
Phase 1Completed2 trials
Phase 1Completed2 trials
Intraocular lymphoma
Phase 1Completed2 trials
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1Completed2 trials
All 23Fewer
Stopped
NCT01126502TerminatedLeukemia, Lymphocytic, Chronic, B-Cell
Administratively Complete.
Trial sponsors
Company2 trialsPhase 233 people
3 trialsPhase 1120 people
1 trialPhase 140 people
Institute of Cancer Research, United Kingdom
1 trialPhase 135 people